

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior listings and versions.

1-39. Cancelled

- 40. (New) An expression vector useful for immunizing a host comprising nucleic acid sequences encoding modified KSA.
- 41. (New) The expression vector of claim 40 wherein the vector is a plasmid or a viral vector.
- 42. (New) The expression vector of claim 41 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
- 43. (New) The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
- 44. (New) The expression vector of claim 43 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
- 45. (New) The expression vector of claim 40 further comprising at least one additional tumor associated antigen.
- 46. (New) The expression vector of claim 45 wherein the tumor associated antigen is selected from the group consisting of carcinoembryonic antigen, a modified carcinoembryonic antigen, or p53.
- 47. (New) The expression vector of claim 40 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
- 48. (New) The expression vector of claim 47 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
- 49. (New) A composition comprising an expression vector of claim 40 in a pharmaceutically acceptable carrier.
- 50. (New) A method for preventing or treating cancer comprising administering to a host a composition of claim 49.
- 51. (New) An isolated DNA molecule encoding SEQ ID NO.: 15.
- 52. (New) An expression vector comprising SEQ ID NO.: 4 and p53 as shown in SEQ ID NO.: 2.
- 53. (New) The expression vector of claim 52 further comprising SEQ ID NO.: 20.

54. (New) The expression vector of claim 52 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
55. (New) The expression vector of claim 53 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
56. (New) The expression vector of claim 54 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
57. (New) The expression vector of claim 55 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
58. (New) A method for preventing or treating cancer comprising administering to a host an expression vector of claim 52.
59. (New) A method for preventing or treating cancer comprising administering to a host an expression vector of claim 53.